Pharmaceutical giant Eli Lilly (LLY) plans reduce its U.S. sales group by nearly 1,000 representatives as part of a major restructuring, according to a report Thursday by Dow Jones Newswires. illy plans to add 300 diabetes sales jobs in addition to layoffs, bringing the net loss of sales representatives to less than 1,000 jobs.
